作者
Eveline AM Heijnsdijk, Elisabeth M Wever, Anssi Auvinen, Jonas Hugosson, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Arnauld Villers, Alvaro Páez, Sue M Moss, Marco Zappa, Teuvo LJ Tammela, Tuukka Mäkinen, Sigrid Carlsson, Ida J Korfage, Marie-Louise Essink-Bot, Suzie J Otto, Gerrit Draisma, Chris H Bangma, Monique J Roobol, Fritz H Schröder, Harry J De Koning
发表日期
2012/8/16
期刊
New England Journal of Medicine
卷号
367
期号
7
页码范围
595-605
出版商
Massachusetts Medical Society
简介
Background
After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain.
Methods
On the basis of ERSPC follow-up data, we used Microsimulation Screening Analysis (MISCAN) to predict the number of prostate cancers, treatments, deaths, and quality-adjusted life-years (QALYs) gained after the introduction of PSA screening. Various screening strategies, efficacies, and quality-of-life assumptions were modeled.
Results
Per 1000 men of all ages who were followed for their entire life span, we predicted that annual screening of men between the ages of 55 and 69 years would result in nine fewer …
学术搜索中的文章
EAM Heijnsdijk, EM Wever, A Auvinen, J Hugosson… - New England Journal of Medicine, 2012